DBV Technologies S.A. (0QAJ.IL)

1,2120 -0,0060 (-0,49%) Alla chiusura: 04:45PM BST

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 88

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Daniel Tassé	CEO & Director	1,21M	N/D	1960
Mr. Sébastien Robitaille	Chief Financial Officer	335,17k	N/D	1970
Dr. Pharis Mohideen	Chief Medical Officer	725,12k	N/D	1965
Mr. Pascal Wotling	Chief Technical Operations Officer & Chief Quality Officer	N/D	N/D	N/D
Ms. Michele F. Robertson	Chief Legal Officer	N/D	N/D	N/D
Ms. Caroline Daniere	Chief HR Officer & Chief of Staff	N/D	N/D	1975
Dr. Wence Agbotounou	Chief Clinical Trial Officer & Sr. VP	N/D	N/D	N/D
Mr. Edward P. Jordan M.B.A.	Sr. VP of Commercial Operations North America	N/D	N/D	1968
Alan Kerr	Sr. VP & Head of Global Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Governance aziendale

L'ISS Governance QualityScore di DBV Technologies S.A. al 1 ottobre 2023 è 9. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.